From the impact of Obamacare to cutting-edge research, biotech buyouts to Big Pharma court battles, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments in health care and their implications for long-term investors. In this week's edition, the team talks about the biggest headlines, stocks that have both popped and dropped, and companies our analysts will be watching in the coming days.
In the following segment, health-care analyst David Williamson discusses the exciting news for seasonal allergy sufferers. Watch and find out how this brand-new drug is poised to help Merck, and investors, reap pollen profits.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.